Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 14/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 14/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 14/20 | 0.49 |
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16692504 | 1.00 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| SCHEMBL23222060 | 0.86 | AOC3 (0.40) | OPRM1OPRD1OPRK1OPRL1AOC3 | |
| SCHEMBL499546 | 0.85 | TAAR1 (0.47) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| SCHEMBL8037342 | 0.85 | OPRM1 (0.50) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| SCHEMBL5101972 | 0.85 | OPRM1 (0.50) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| SCHEMBL16649685 | 0.85 | TAAR1 (0.47) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| SCHEMBL1974847 | 0.85 | OPRM1 (0.50) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| SCHEMBL25269085 | 0.83 | PNMT (0.47) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| Hydrochloric Acid SCHEMBL23527440 | 0.83 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1PNMT | |
| Hydrochloric Acid SCHEMBL4535082 | 0.83 | OPRM1 (0.49) | OPRM1OPRD1OPRK1OPRL1PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569917-B1 | PYRAZINE-BASED TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2016-12-07 | — | — | EP | disclosed |
| EP-1569917-B1 | PYRAZINE-BASED TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2016-12-07 | — | — | EP | disclosed |
| US-8084456-B2 | Pyrazine-based tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-12-27 | — | — | US | disclosed |
| US-8084456-B2 | Pyrazine-based tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-12-27 | — | — | US | disclosed |
| US-8084456-B2 | Pyrazine-based tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-12-27 | — | — | US | disclosed |
| US-20070082894-A1 | Pyrazine-based tubulin inhibitors | CYTOPIA PTY LTD (AU) | 2007-04-12 | — | — | US | disclosed |
| US-20070082894-A1 | Pyrazine-based tubulin inhibitors | CYTOPIA PTY LTD (AU) | 2007-04-12 | — | — | US | disclosed |
| US-20070082894-A1 | Pyrazine-based tubulin inhibitors | CYTOPIA PTY LTD (AU) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082894-A1 | Pyrazine-based tubulin inhibitors | TUBB1, TUBA1C, TUBB | OPRM1 4210/4885OPRD1 3431/4885OPRK1 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.